fiercebiotech.com
Cure8 news brief
TScan's strategy unaffected by Amgen scrapping $500M+ collab - Fierce Biotech
Research and clinical trials
Drug Discovery
Market or Business News
Crohn's disease
Inflammatory bowel disease
Why This Matters
This article reports that Amgen is ending a Crohn’s disease target-discovery collaboration with TScan, which could slow or change an industry pathway for immune-targeted therapies discovered through that partnership. TScan says its own programs aren’t affected, so near-term patient impact is limited.
Who Should Pay Attention
Researchers and clinicians working on T‑cell/immune-target discovery; patients and caregivers tracking Crohn’s disease research and industry partnerships; biotech investors and developers.
Study Snapshot
Story typeBusiness news
Evidence typeMarket or Business News
Source depthFull source text
What To Know
TScan received an upfront payment from Amgen in 2023 to use its TargetScan platform to identify antigens recognized by T cells in Crohn’s disease. Amgen informed TScan it is ending the collaboration after a strategic portfolio review; the partnership will officially end Nov. 10, per TScan’s SEC filing.
TScan says the termination does not affect its own development programs, which focus mainly on oncology, and that there are no planned changes to its wholly owned Crohn’s‑related target-discovery work. The story is primarily about business and R&D strategy rather than clinical results or new patient treatments.
Keep In Mind
The piece is market-focused reporting based on company statements and an SEC filing. It does not present clinical data or new findings about treatments; TScan’s core therapeutic programs are largely oncology-focused. The termination reflects strategic priorities at Amgen rather than published scientific results.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationfiercebiotech.com
PublisherFierce Biotech
Indexed viaGoogle News
Source typeWeb article
PublishedAug 20, 2026, 2:48 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Library of Organoid “Mini-Guts” Helps Identify New Pathways in IBD
This research uses patient-derived “mini-guts” to uncover epigenetic changes that may help explain differences between people with Crohn’s disease and could point to new biological pathways for future therapies.
Research into protein could lead to new treatments
The study identifies a specific protein interaction that may underlie persistent inflammation; for people with Crohn’s and other inflammatory conditions this points to a potential new, more targeted treatment approach in...
Research Charts Cellular Pathways in Crohn's Fibrosis
The study maps cell types and signals linked to submucosal scarring in Crohn's disease, a complication without drug treatments that often requires surgery. Understanding these mechanisms could point to future therapeutic...